LAMTOR4 and prostate carcinoma: Considering the well-established associations of PTEN (loss) and ERG (gain) with the outcomes and prognosis of prostate cancer patients, we attempted to investigate the prognostic relevance of LAMTOR4 in conjunction with PTEN or ERG.